Kamada Reports Strong 2025 Financial Results, Issues Positive 2026 Guidance, and Initiates Annual Cash Dividend Policy

summarizeSummary

Kamada reported strong 2025 financial results, issued positive 2026 guidance, and initiated an annual cash dividend policy, signaling confidence despite an R&D setback for its Inhaled AAT program.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported total revenues of $180.5 million for 2025, a 12% increase from 2024, and net income of $20.2 million, a 39.3% increase year-over-year.

• Positive 2026 Financial Guidance

  Projected 2026 total revenues in the range of $200 million to $205 million and adjusted EBITDA between $50 million and $53 million, representing year-over-year increases of 13% and 23% respectively at the midpoint.

• New Annual Cash Dividend Policy

  Adopted a policy to distribute at least 50% of annual net income as a cash dividend, and declared a $0.25 per share dividend (approximately $14.4 million in aggregate) payable on April 6, 2026.

• Discontinuation of Phase 3 Inhaled AAT Trial

  Announced the discontinuation of the Phase 3 InnovAATe trial for Inhaled AAT in December 2025, following an interim futility analysis indicating it was unlikely to meet its primary endpoint.

auto_awesomeAnalysis

Kamada Ltd. has filed its annual 20-F report, revealing robust financial performance for 2025 with significant revenue and net income growth. The company also provided an optimistic outlook for 2026, projecting double-digit increases in both revenue and adjusted EBITDA. A key highlight is the adoption of a new annual cash dividend policy, committing to distribute at least 50% of its net income, and the declaration of a $0.25 per share dividend. While the discontinuation of the Phase 3 InnovAATe trial for Inhaled AAT due to futility is a notable R&D setback, the company's strategic expansion in plasma collection operations and the launch of new biosimilar products are expected to drive future growth. The overall financial health and commitment to shareholder returns signal a positive trajectory despite specific product challenges and geopolitical risks in its operating region.